A prognostic model based on readily available clinical data enriched a preemptive pharmacogenetic testing program

Journal of clinical Epidemiology – A growing body of literature relates human genetic variation to drug response. Currently, more than 100 drugs have pharmacogenomic (PGx) information that affects prescribing in Food and Drug Administration (FDA) labels. Such evidence was the impetus behind Vanderbilt University Medical Center’s Pharmacogenomic Resource for Enhanced Decisions in Care & Treatment (PREDICT) program, a quality improvement initiative utilizing preemptive, panel-based genotyping to deliver genotype-tailored prescribing guidance at the point of care.